- Home
- NBH vs ACRS Comparison
NBH vs ACRS Comparison
Compare NBH & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBH | ACRS |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 314.2M | 314.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBH | ACRS |
|---|---|---|
| Price | $10.58 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 85.9K | ★ 3.1M |
| Earning Date | 01-01-0001 | 02-23-2026 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | ★ $15,742,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $87.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.75 | $1.05 |
| 52 Week High | $11.01 | $4.89 |
Technical Indicators
Market Signals| Indicator | NBH | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 68.17 | 48.13 |
| Support Level | $10.38 | $3.25 |
| Resistance Level | $10.63 | $3.78 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 95.22 | 13.52 |
Price Performance
Historical ComparisonAbout NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.